ASH Annual Meeting

Highlights and interviews from the American Society of Hematology’s Annual Meeting.

  • Balancing Bleeding and Thrombosis Risk With Anticoagulation in Patients With Hematologic Malignancies and Thrombocytopenia Tuesday, January 17th, 2017 | January Annual Meeting Edition 2017, Volume 3, Issue 2

    Two studies presented at the 2016 ASH Annual Meeting examined the safety of anticoagulation therapy in patients with hematologic malignancies – a population with an increased risk of venous thromboembolism (VTE), despite periods of thrombocytopenia in subsets. While the first study supports the safety of anticoagulation, the second study questions the use of a “standard” […]

  • Results from Phase III SWOG Trial: 7+3 Still the Standard of Care for Patients With Acute Myeloid Leukemia Tuesday, January 17th, 2017 | January Annual Meeting Edition 2017, Volume 3, Issue 2

    Remission induction with 7+3 chemotherapy (cytarabine + daunorubicin) should remain the standard of care for younger patients with acute myeloid leukemia (AML), according to results from the phase III SWOG S1203 trial, which evaluated whether adding the histone deacetylase (HDAC) inhibitor vorinostat to a regimen of idarubicin and high-dose cytarabine, or whether idarubicin and high-dose […]

  • Subcutaneous Delivery of Daratumumab Is Safe, Effective in Multiple Myeloma Tuesday, January 17th, 2017 | January Annual Meeting Edition 2017, Volume 3, Issue 2

    While daratumumab was approved by the U.S. Food and Drug Administration (FDA) as an intravenous (IV) infusion for the treatment of multiple myeloma (MM), the infusion can take several hours, potentially affecting patient quality of life and adding costs to the therapy. According to results from the open-label, multicenter, dose-escalation phase Ib PAVO study, subcutaneous […]

  • Large Registry Analysis Confirms Autologous Hematopoietic Cell Transplantation Is Feasible in Older Patients Tuesday, January 17th, 2017 | January Annual Meeting Edition 2017, Volume 3, Issue 2

    Older patients (≥65 years) with hematologic malignancies are often considered unsuitable for autologous hematopoietic cell transplantation (AHCT) because of the potential for higher risks of complications. As a result, they are often excluded from or under-represented in clinical trials studying transplantation. A large cohort study presented at the 2016 ASH Annual Meeting specifically examined overall […]

  • Living Longer, Living Better: Should Lenalidomide Be Standard of Care for Patients With Myeloma? Monday, January 9th, 2017 | January Annual Meeting Edition 2017, Volume 3, Issue 2

    Results from two studies presented at the 2016 ASH Annual Meeting support incorporating lenalidomide maintenance therapy for patients with multiple myeloma (MM). First, the large phase III Myeloma XI study demonstrated that the use of lenalidomide maintenance therapy significantly improved progression-free survival (PFS) compared with no lenalidomide maintenance1; second, an analysis of the Connect® MM […]

1 of 15
back to top